Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to ...
Posted by Michael Wonder on 12 Apr 2022
NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance
12 April 2022 - Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be ...
Posted by Michael Wonder on 12 Apr 2022
Myovant Sciences and Pfizer provide update on supplemental new drug application for Myfembree for the management of moderate to severe pain associated with endometriosis
12 April 2022 - Myovant Sciences and Pfizer announced today an update on the Supplemental new drug application for Myfembree ...
Posted by Michael Wonder on 12 Apr 2022
Aeglea BioTherapeutics submits BLA to FDA for pegzilarginase for the treatment of arginase 1 deficiency
12 April 2022 - European marketing application on track for submission this year. ...
Posted by Michael Wonder on 12 Apr 2022
FDA grants Direct Biologics regenerative medicine advanced therapy designation for the use of ExoFlo in COVID-19 related ARDS
12 April 2022 - Direct Biologics announced that the U.S. FDA has awarded their EV drug product ExoFlo with a regenerative ...
Posted by Michael Wonder on 12 Apr 2022
TGA approves new medicine for patients with SLE
12 April 2022 - Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the type ...
Posted by Michael Wonder on 12 Apr 2022
It’s time to fix the FDA by breaking it up
11 April 2022 - A new investigation about the agency’s failures underscores the need for a separate agency to keep our ...
Posted by Michael Wonder on 12 Apr 2022
Recursion is granted fast track designation for REC-4881 for the potential treatment of familial adenomatous polyposis
11 April 2022 - Recursion today announced that the U.S. FDA has granted the company fast track designation for REC-4881 ...
Posted by Michael Wonder on 11 Apr 2022
The EQ-HWB: overview of the development of a measure of health and wellbeing and key results
8 April 2022 - This article presents an overview of the international development of a new generic measure, the EQ Health ...
Posted by Michael Wonder on 11 Apr 2022
Drug pricing with evidence development
11 April 2022 - The policy controversy surrounding aducanumab for Alzheimer disease has shifted from the FDA, which authorised the ...
Posted by Michael Wonder on 11 Apr 2022
Health Canada approves Gardasil 9 (human papillomavirus 9 valent vaccine, recombinant) for the prevention of oropharyngeal and other head and neck cancers
11 April 2022 - Gardasil 9 is the first vaccine in Canada approved for the prevention of HPV related oropharyngeal ...
Posted by Michael Wonder on 11 Apr 2022
A review of patient reported outcome labelling of FDA approved new drugs (2016-2020): counts, categories and comprehensibility
8 April 2022 - A review of new drug approvals by the U.S. FDA for 2006 to 2015 showed that approximately ...
Posted by Michael Wonder on 11 Apr 2022
SMC - April 2022 decisions
12 April 2022 - Advice on three new medicines for use in conditions including a rare and fatal genetic condition affecting ...
Posted by Michael Wonder on 11 Apr 2022
Eton Pharmaceuticals announces FDA approval of cysteine hydrochloride injection
11 April 2022 - Eton Pharmaceuticals today announced that it has received final approval from the U.S. FDA for its cysteine ...
Posted by Michael Wonder on 11 Apr 2022
Poxel announces PXL770 awarded FDA fast track designation for X-linked adrenoleukodystrophy
11 April 2022 - Poxel is pleased to announce that the U.S. FDA has granted fast track designation to PXL770 ...